Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-32

Looks to be a systematical approach by the Race team to outline to all (investors, collaborators, clinicians, large pharma etc.) that Bisantrene is truly unique.

Where other cardioprotective drugs have fallen over, Bisantrene is continuing to power forward. The Race team are demonstrating that the drug is cancer killing when combined with existing standard of care drugs, while simultaneously demonstrating that it protects the heart when combined with existing standard of care drugs. My view, like some others here, is that the risk of Bisantrene falling over in the clinic is low given previous trials (Sheba and historical) so this is really shaping up to be something remarkable... for those afflicted by cancer, oncologists and cancer specialists, RAC investors and large pharma (who's drugs stand to become far more valuable).

DYOR - it pays off in the long run.